

PHARMACY POLICY STATEMENT

Common Ground Healthcare Cooperative (CGHC)

| | |
|------------------|------------------------------|
| DRUG NAME | Stelara (ustekinumab) |
| BENEFIT TYPE | Medical or Pharmacy |
| STATUS | Prior Authorization Required |

Stelara is a human interleukin-12 and interleukin-23 antagonist initially approved by the FDA in 2009. It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis. Pediatric patients 6 years and older are also approved to have Stelara for moderate to severe plaque psoriasis treatment.

Stelara (ustekinumab) will be considered for coverage when the following criteria are met:

Crohn's Disease (CD)

For **initial** authorization:

1. Member is 18 years of age or older with moderately to severely active CD; AND
2. Medication must be prescribed by or in consultation with a gastroenterologist; AND
3. Must have had a negative TB test within the last 12 months; AND
4. Member has had a documented trial and inadequate response, or intolerance to at least **one** of the following conventional therapies: a 4-week trial of a corticosteroid OR a 12-week trial of 6-mercaptopurine, azathioprine, or methotrexate. Note: Trial is not required if member is switching from another biologic agent; OR
5. Member has severe disease that requires immediate use of a biologic agent, as indicated by one of the following:
 - a) Extensive small bowel disease involving more than 100 cm;
 - b) History of bowel or colon resection and is at high risk for CD recurrence (e.g., smoker, <30 years old, 2 or more resections, penetrating/fistulizing disease, etc.);
 - c) Fistulizing disease.
6. **Dosage allowed/Quantity limit:**
 - a) Induction (medical benefit): a one-time IV infusion based on weight. Up to 55 kg = 260 mg (2 vials); greater than 55 kg to 85 kg = 390 mg (3 vials); greater than 85 kg = 520 mg (4 vials);
 - b) Maintenance (pharmacy or medical benefit): subcutaneous injection of 90 mg dose 8 weeks after induction and every 8 weeks thereafter.

Note to reviewer: A one-time induction dose is approved on the medical benefit. Maintenance therapy is approved on either pharmacy OR medical benefit. Please inactivate any duplicate prior authorization.

If all the above requirements are met, the medication will be approved for 12 months.

For **reauthorization**:

1. Chart notes have been provided showing improvement in signs and symptoms of CD (defined as mucosal healing, fewer flare-ups of symptoms, improved quality of life, etc.).

If all the above requirements are met, the medication will be approved for an additional 12 months.

Plaque Psoriasis (PsO)

For **initial** authorization:

1. Member must be 6 years of age or older; AND
2. Medication must be prescribed by or in consultation with a dermatologist; AND
3. Member has clinical documentation of moderate to severe plaque psoriasis characterized by 3% or more of body surface area (BSA) or disease affecting sensitive areas (e.g., hands, feet, face, genitals, etc.); AND
4. Member has tried and failed to respond to treatment with at least **ONE** of the following:
 - a) At least 12 weeks of photochemotherapy (i.e., psoralen plus ultraviolet A therapy);
 - b) At least 12 weeks of phototherapy (i.e., UVB light therapy, Excimer laser treatments);
 - c) At least a 4-week trial with topical antipsoriatic agents (i.e., anthralin, calcipotriene, coal tar, corticosteroids, tazarotene, tacrolimus, pimecrolimus);
 - d) At least a 12-week trial of a systemic non-biologic DMARD (i.e., cyclosporine, methotrexate, acitretin); AND
5. Must have had a negative tuberculosis test within the last 12 months.
6. **Dosage allowed/Quantity limit:**
 - a) Adults: 100 kg or less: 45 mg subcutaneously at 0 and 4 weeks, and then every 12 weeks thereafter; more than 100 kg: 90 mg subcutaneously at 0 and 4 weeks, and then every 12 weeks thereafter;
 - b) Pediatrics (6 to 17): subcutaneous dose by weight at week 0, week 4, and every 12 weeks thereafter. Less than 60 kg: 0.75 mg/kg; 60 kg to 100 kg: 45 mg; more than 100 kg: 90 mg.

If all the above requirements are met, the medication will be approved for 12 months.

For **reauthorization**:

1. Chart notes have been provided showing improvement of signs and symptoms of disease (e.g., documented member's BSA improvement, etc.).

If all the above requirements are met, the medication will be approved for an additional 12 months.

Psoriatic Arthritis (PsA)

For **initial** authorization:

1. Member must be 6 years of age or older; AND
2. Medication must be prescribed by or in consultation with a rheumatologist or a dermatologist; AND
3. Member has a documented diagnosis of active psoriatic arthritis (PsA); AND
4. Must have had a negative TB test within the last 12 months; AND

5. Member has met a 4-week trial of an NSAID taken at maximally tolerated doses AND a 3-month trial of a non-biologic DMARD agent (e.g., methotrexate, sulfasalazine, cyclosporine, etc.) unless one of the following situations is met:
- a) Non-biologic DMARD is not required for:
 - i) Concomitant axial disease (i.e., involving sacroiliac joint and spine) or enthesitis; OR
 - b) NSAID and non-biologic DMARD are not required for:
 - i) Severe PsA (defined as having at least one of the following: erosive disease, active PsA at many sites including dactylitis or enthesitis, elevated levels of ESR or CRP, joint deformities, or major impairment in quality of life).
6. **Dosage allowed/Quantity limit:**
- a) Adults: 45 mg subcutaneously at 0 and 4 weeks, and then every 12 weeks thereafter. If member has co-existent moderate-to-severe PsO, use the dosing regimen for adult PsO.
 - b) Pediatrics (6 to 17): subcutaneous dose by weight at week 0, week 4, and every 12 weeks thereafter.

| <u>Weight Range (kilograms)</u> | <u>Dosage Regimen</u> |
|--|-----------------------|
| Less than 60 kg | 0.75 mg/kg |
| 60 kg or more | 45 mg |
| Greater than 100 kg with co-existent moderate-to-severe plaque psoriasis | 90 mg |

If all the above requirements are met, the medication will be approved for 12 months.

For **reauthorization**:

1. Chart notes have been provided showing improvement of signs and symptoms of disease (e.g., documented member's BSA improvement, etc.).

If all the above requirements are met, the medication will be approved for an additional 12 months.

Ulcerative Colitis (UC)

For **initial** authorization:

1. Member is 18 years of age or older with moderately to severely active UC; AND
2. Medication must be prescribed by or in consultation with a gastroenterologist; AND
3. Must have had a negative TB test within the last 12 months; AND
4. Member have had a documented trial and inadequate response with **one** of the following:
 - a) 3 months of 6-mercaptopurine or azathioprine;
 - b) 30 days of corticosteroid (e.g., budesonide, prednisone, methylprednisolone, etc.);
 - c) 3 months of 5-aminosalicylate (e.g., Asacol HD, Lialda, Pentasa, Delzicol, mesalamine, etc.).
5. **Dosage allowed/Quantity limit:**
 - a) Induction (medical benefit): a one-time IV infusion based on weight. 55 kg or less = 260 mg (2 vials); greater than 55 kg to 85 kg = 390 mg (3 vials); greater than 85 kg = 520 mg (4 vials);
 - b) Maintenance (pharmacy or medical benefit): subcutaneous injection of 90 mg dose 8 weeks after induction and every 8 weeks thereafter.

Note to reviewer: A one-time induction dose is approved on the medical benefit. Maintenance therapy is approved on either pharmacy OR medical benefit. Please inactivate any duplicate prior authorization.

If all the above requirements are met, the medication will be approved for 12 months.

For **reauthorization**:

1. Chart notes have been provided showing improvement in signs and symptoms of UC (defined as clinical remission, decrease in rectal bleeding, decreased corticosteroid use, etc.).

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Stelara (ustekinumab) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

| DATE | ACTION/DESCRIPTION |
|------------|---|
| 05/10/2017 | Policy for Stelara created. Policies SRx-0042 and SRx-0043 archived. New diagnosis of Crohn's disease was added. For diagnosis of PsO: immunosuppressive criterion was separated from phototherapies and topical agents trials; TNF inhibitors Humira and Enbrel were listed as required trials; Psoriasis Area and Severity Index (PASI) score requirement was added. For diagnosis of PsA: TNF inhibitors Humira and Enbrel were listed as required trials. List of diagnoses considered not medically necessary was added. |
| 11/13/2017 | Age requirement for diagnosis of PsO updated. |
| 02/26/2019 | Humira was removed from criteria; Cimzia, Cosentyx, Otezla, Siliq and Xeljanz added to trial agents list. TB test allowed to be done within 12 months prior to initiation of therapy; chest x-ray option removed. Other drugs options allowed for PsA if there is an intolerance or contraindication to methotrexate. |
| 10/31/2019 | New indication of Ulcerative Colitis added. |
| 11/23/2020 | Removed repeat TB for reauth for all diagnoses. For <u>CD</u> : specified length of trials for conventional therapies, previously not specified. For severe disease, removed esophageal/gastroduodenal disease, specified that history of colonic resection must also be high risk for recurrence. Updated dosage section and added note for internal PA review. For <u>PsO</u> : Age requirement expanded to include 6 years or older. Removed rheumatologist from prescriber. Changed BSA to 3% or sensitive area involvement. Removed PASI score requirement. For <u>PsA</u> : Added requirement of diagnosis of PsA. Changed the trial section to be 4 weeks of an NSAID AND 3 months of a DMARD unless other circumstances apply (e.g., concomitant axial disease, severe PsA, etc.). For <u>UC</u> : removed Mayo score requirement; removed TNF as a trial option; specified the length of trials for conventional therapies (previously not specified). Updated dosage section and added note for internal PA review. |
| 03/05/2022 | Transferred to new template. Updated references. Simplified wording for TB test and DMARD requirements. Removed initial criteria requirement from reauthorization. Removed TNF trial requirement for CD. |
| 03/17/2022 | Removed preferred biologic trials. |

| | |
|-------------------|--|
| 08/19/2022 | Lowered age for PsA to at least 6 years of age. Updated dosing section. Updated references. |
| 09/26/2024 | PsO: converted double trial of topicals + systemic therapy to a single trial with both topical and systemic options. |

References:

1. Stelara [package insert]. Horsham, PA: Janssen Biotech Inc; 2024.
2. Sulz MC, Burri E, Michetti P, et al. Treatment Algorithms for Crohn's Disease. *Digestion*. 2020;101 Suppl 1:43-57.
3. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2018;113(4):481-517.
4. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. *J Crohns Colitis*. 2020;14(1):4-22.
5. Pimentel AM, Rocha R, Santana GO. Crohn's disease of esophagus, stomach and duodenum. *World J Gastrointest Pharmacol Ther*. 2019;10(2):35-49.
6. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT; AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF- α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. *Gastroenterology*. 2013;145(6):1459-1463.
7. Regueiro M, Velayos F, Greer JB, et al. American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection. *Gastroenterology*. 2017;152(1):277-295.e3.
8. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. *N Engl J Med* 2016; 375:1946-1960.
9. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. *Gastroenterology*. 2008 Oct;135(4):1130-41. Epub 2008 Jul 17.
10. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures [published online ahead of print, 2020 Jul 30]. *J Am Acad Dermatol*. 2020;S0190-9622(20)32288-X.
11. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol*. 2020;82(6):1445-1486.
12. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072.
13. Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy [published correction appears in *J Am Acad Dermatol*. 2020 Mar;82(3):780]. *J Am Acad Dermatol*. 2019;81(3):775-804.
14. Menter A, Cordoro KM, Davis DM, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis in pediatric patients. *J Am Acad Dermatol* 2020;82:161-201.
15. Leonardi CL, Kimball AB, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX-1). *Lancet* 2008;371:1665-74.
16. Gladman DD, Ritchlin C. Clinical manifestations and diagnosis of psoriatic arthritis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed September 23, 2020.
17. Gladman DD, Ritchlin C. Treatment of psoriatic arthritis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed September 23, 2020.
18. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. *Arthritis Rheumatol*. 2016 May;68(5):1060-71.
19. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of Psoriatic Arthritis. *Arthritis Rheumatol*. 2019 Jan;71(1):5-32.



HEALTHCARE COOPERATIVE

20. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet*. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13.
21. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol*. 2019;114(3):384-413.
22. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology*. 2020;158(5):1450-1461.

Effective date: 01/01/2025

Revised date: 09/26/2024